Heron Therapeutics | HRTX - Selling And Administration Expenses


Heron Therapeutics reported $23.74M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
ALKERMES USD 190.54M 6.1M Sep/2026
Alnylam Pharmaceuticals USD 342M 5.92M Sep/2026
Amarin USD 18.97M 1.03M Dec/2025
ANI Pharmaceuticals USD 94.86M 3.2M Sep/2026
Anika Therapeutics USD 10.01M 14K Dec/2025
Arrowhead Research USD 46.63M 4.88M Jun/2026
Eisai JPY 114.83B 4.71B Jun/2026
Emergent BioSolutions USD 182.8M 82.3M Jun/2023
GlaxoSmithKline GBP 2.16B 39M Sep/2026
Heron Therapeutics USD 23.74M 605K Dec/2025
Insmed USD 253.03M 5.56M Sep/2026
Ligand Pharmaceuticals USD 72.62M 43.49M Sep/2026
Merck USD 2.86B 25M Sep/2026
Nektar Therapeutics USD 11.87M 1.7M Mar/2026
Neurocrine Biosciences USD 366.3M 16.8M Sep/2026
Omeros USD 11.32M 2.48M Sep/2024
Pacira USD 950.8M 858.99M Sep/2026
Regeneron Pharmaceuticals USD 662.1M 14.4M Jun/2026
Roche Holding CHF 6.37B 908M Jun/2026
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Ultragenyx Pharmaceutical USD 97M 9M Sep/2026
Veracyte USD 57.95M 2.25M Sep/2026
Vertex Pharmaceuticals USD 556.3M 25.9M Sep/2026